Angiotensin-converting enzyme inhibitor versus calcium antagonist in the treatment of hypertension.

Détails

ID Serval
serval:BIB_10BFD37CEF57
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Angiotensin-converting enzyme inhibitor versus calcium antagonist in the treatment of hypertension.
Périodique
Nephron
Auteur⸱e⸱s
Brunner H.R., Bidiville J., Waeber G., Porchet M., Nussberger J., Waeber B.
ISSN
0028-2766
Statut éditorial
Publié
Date de publication
1987
Peer-reviewed
Oui
Volume
47
Numéro
Suppl 1
Pages
87-9
Langue
anglais
Notes
Publication types: Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
Sixteen patients with essential hypertension were treated for 2 consecutive 6-week periods with either the angiotensin-converting enzyme (ACE) inhibitor enalapril (20 mg once daily) or the calcium antagonist diltiazem (120 mg twice daily). The sequence of the treatment phases was randomly allocated. Blood pressure decreased from 154/102 +/- 5/2 mm Hg (mean +/- SEM) to 135/96 +/- 4/2 and 140/98 +/- 3/2 mm Hg during treatment with enalapril and diltiazem, respectively. It was impossible in the individual hypertensive patient to predict the long-term blood pressure response to one of the agents studied based on the long-term blood pressure response to the other agent.
Mots-clé
Adult, Blood Pressure, Diltiazem, Enalapril, Female, Humans, Hypertension, Male, Middle Aged
Pubmed
Web of science
Création de la notice
05/03/2008 17:40
Dernière modification de la notice
24/02/2024 8:33
Données d'usage